Literature DB >> 2915559

Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass.

R K Wenger1, H Lukasiewicz, B S Mikuta, S Niewiarowski, L H Edmunds.   

Abstract

In 10 patients, cardiopulmonary bypass decreased the number of fibrinogen binding sites from 31,730 +/- 12,802 per platelet to 18,590 +/- 9,644 per platelet. Bypass also decreased the amount of the platelet membrane glycoprotein IIIa, which is part of the fibrinogen receptor complex, from 17.1 +/- 3.6 ng/10(9) platelets to 12.9 +/- 4.7. The fibrinogen binding constant did not change. Platelet sensitivity to adenosine diphosphate did not change; however, template bleeding times increased from 5.2 +/- 1.5 minutes before bypass to 8.5 +/- 2.3 minutes after bypass. Analysis of detergent washings from the perfusion circuit after bypass in five patients indicated that platelet material remains attached to the surface as membrane fragments and degranulated platelets. These data further elucidate the mechanism of platelet loss and dysfunction during cardiopulmonary bypass and highlight the importance of platelet membrane fibrinogen receptors and surface adsorbed fibrinogen in this process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2915559

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

1.  In vivo comparison study of FDA-approved surface-modifying additives and poly-2-methoxyethylacrylate circuit surfaces coatings during cardiopulmonary bypass.

Authors:  Angela Ask; David Holt; Lynette Smith
Journal:  J Extra Corpor Technol       Date:  2006-03

2.  Phosphodiesterase-inhibitors enoximone and piroximone in cardiac surgery: influence on platelet count and function.

Authors:  J Boldt; C Knothe; B Zickmann; C Herold; E Dapper; G Hempelmann
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 3.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

4.  Effect of Gabexate mesilate on postoperative blood loss in cardiovascular surgery using cardiopulmonary bypass.

Authors:  A Kohyama; R Goh; K Mori; S Yasumoto; H Kimura; H Kitahata
Journal:  J Anesth       Date:  1994-09       Impact factor: 2.078

Review 5.  Antifibrinolytic therapy in cardiac surgery.

Authors:  R H Chen; O H Frazier; D A Cooley
Journal:  Tex Heart Inst J       Date:  1995

6.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Authors:  C S Rinder; H M Rinder; B R Smith; J C Fitch; M J Smith; J B Tracey; L A Matis; S P Squinto; S A Rollins
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Combination of acute preoperative plateletpheresis, cell salvage, and aprotinin minimizes blood loss and requirement during cardiac surgery.

Authors:  Shu Li; Hongwen Ji; Jing Lin; Eric Lenehan; Bingyang Ji; Jinping Liu; Jin Liu; Cun Long; Terry A Crane
Journal:  J Extra Corpor Technol       Date:  2005-03

8.  Clinical experience of Argatroban for anticoagulation in cardiovascular surgery.

Authors:  H Ohteki; K Furukawa; H Ohnishi; Y Narita; M Sakai; K Doi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-01

9.  Activation and shedding of platelet glycoprotein IIb/IIIa under non-physiological shear stress.

Authors:  Zengsheng Chen; Nandan K Mondal; Jun Ding; Steven C Koenig; Mark S Slaughter; Bartley P Griffith; Zhongjun J Wu
Journal:  Mol Cell Biochem       Date:  2015-07-10       Impact factor: 3.396

Review 10.  Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.

Authors:  R Davis; R Whittington
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.